ArticleNature medicine2019
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 128 papers.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 210 citations in OpenAlex.
- Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Nature medicine · 2021Trial
- Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection.Frontiers in immunology · 2021Trial
- A Tumor-Boundary Niche Enriched for PD-1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- Peripheral T-Cell Receptor β Repertoire Dynamics Correlate with Response to Anti-PD-L1 Therapy in Non-Small Cell Lung Cancer.Cancers · 2026Article
- Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer.NPJ precision oncology · 2026Article
- Inverse relationship between neoantigen clonality and T-cell activity reveals distinct immune phenotypes in HNSCC.Journal of translational medicine · 2026Article
- LCPBert: ProtBERT-based early-stage lung cancer prediction from T cell receptor beta sequences.iScience · 2026Article
- Current and future immunotherapies for NSCLC.Journal of hematology & oncology · 2026Review
- Article
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma.Nature communications · 2026Article
- SLC2A1Nature cell biology · 2026Article
- Stable global repertoire architecture masks short-term clonal remodeling in intratumoral TCR repertoires.Frontiers in immunology · 2026Article
- Germline based SARS-CoV-2 specific B cell repertoire motif identified with novel sequence based bioinformatic pipeline.Frontiers in immunology · 2026Article
- Genome instability and crosstalk with the immune response.Genome medicine · 2025Review
- Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application.Biomarker research · 2025Review
- T-cell Receptor Profiling of Blood to Detect Lung Cancer.Cancer immunology research · 2025Article
- Insights into the Mechanisms of Immune-Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception.Cancer cell · 2025Article
- Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
68 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
35 authors at 7 institutions in 2 countries.
Kroopa Joshi *Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Marc Robert de Massy *Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-3048-1680
Mazlina Ismail *Division of Infection and Immunity, University College London, London, UK.
James L ReadingCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Imran UddinDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0003-0736-3149
Annemarie WoolstonDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-8932-2895
Emine HatipogluCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Theres OakesDivision of Infection and Immunity, University College London, London, UK.
Rachel RosenthalCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Thomas PeacockDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0001-9385-116X
Tahel RonelDivision of Infection and Immunity, University College London, London, UK.
Mahdad NoursadeghiDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-4774-0853
Virginia TuratiDepartment of Cancer Biology, University College London Cancer Institute, London, UK.
Andrew J S FurnessCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Andrew GeorgiouCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Yien Ning Sophia WongCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Assma Ben AissaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Mariana Werner SunderlandCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nicolai J BirkbakCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Gareth A WilsonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Crispin T HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Ehsan GhoraniCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-5373-5762
José Afonso Guerra-AssunçãoBill Lyons Informatics Centre, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6593-403X
Javier HerreroBill Lyons Informatics Centre, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-7313-717X
Tariq EnverUniversity College London Cancer Institute, London, UK.
Sine R HadrupDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.ORCID http://orcid.org/0000-0002-5937-4344
Allan HackshawCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Karl S PeggsCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. c.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
TRACERx consortium
Sergio A QuezadaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.ORCID http://orcid.org/0000-0002-9763-1700
Benny ChainDivision of Infection and Immunity, University College London, London, UK. b.chain@ucl.ac.uk.ORCID http://orcid.org/0000-0002-7417-3970
London Cancer · GBCancer Research UK · GBUniversity College London · GBRoyal Marsden NHS Foundation Trust · GBThe Francis Crick Institute · GBTechnical University of Denmark · DKThe London College · GB
Funding
Arthritis Research UK FC001169Cancer Research UK 16463Cancer Research UK 17786Cancer Research UK 19310Cancer Research UK 20265Cancer Research UK 20466Cancer Research UK 20764Cancer Research UK 21999Cancer Research UK 22246Cancer Research UK 24314Cancer Research UK 24956Cancer Research UK 25253Cancer Research UK 28990Cancer Research UK 30025Cancer Research UK A17786Cancer Research UK A20764Cancer Research UK A22246Cancer Research UK FC001169Medical Research Council FC001169Medical Research Council MC_UP_1203/1Medical Research Council MR/M009033/1Medical Research Council MR/N000838/1Wellcome TrustWellcome Trust 211179/Z/18/ZWellcome Trust FC001169
Abstract
Somatic mutations together with immunoediting drive extensive heterogeneity within non-small-cell lung cancer (NSCLC). Herein we examine heterogeneity of the T cell antigen receptor (TCR) repertoire. The number of TCR sequences selectively expanded in tumors varies within and between tumors and correlates with the number of nonsynonymous mutations. Expanded TCRs can be subdivided into TCRs found in all tumor regions (ubiquitous) and those present in a subset of regions (regional). The number of ubiquitous and regional TCRs correlates with the number of ubiquitous and regional nonsynonymous mutations, respectively. Expanded TCRs form part of clusters of TCRs of similar sequence, suggestive of a spatially constrained antigen-driven process. CD8
Indexed as
Genetic HeterogeneityImmunotherapy, AdoptiveAgedCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedMutationReceptors, Antigen, T-CellReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.